MCAT and melanoma: Even in patients with low-risk melanomas <1.0 mm (846 of 1270), the majority of those with progression, that is, 21 of 32 (65.6%, χ2=63.9; df=1; P<0.001), and those who died, that is, 11 of 15 (73.3%, χ2=39.0; df=1; P<0.001), showed statistically significant MT overexpression in their primary melanoma.